Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyBiologicalProcessglial cell differentiation

GRN OLIG2

2.34e-0332152GO:0010001
GeneOntologyBiologicalProcessgliogenesis

GRN OLIG2

4.25e-0343552GO:0042063
HumanPhenoDeficit in grammar

GRN GALT

8.32e-06932HP:0006977
PathwayREACTOME_SIGNALING_BY_RECEPTOR_TYROSINE_KINASES

MEGF6 MST1R

8.27e-0341852MM15587
Pubmed

SorCS2 binds progranulin to regulate motor neuron development.

GRN OLIG2

9.09e-07115237897724
Pubmed

Hereditary Dystonia Overview

GRN GALT

5.47e-05825220301334
Pubmed

Identification of multi-SH3 domain-containing protein interactome in pancreatic cancer: a yeast two-hybrid approach.

GRN MEGF6

9.15e-051065218654987
Pubmed

Comparison of an expanded ataxia interactome with patient medical records reveals a relationship between macular degeneration and ataxia.

GRN MEGF6

1.13e-041185221078624
InteractionMFAP5 interactions

GRN MEGF6

6.50e-055252int:MFAP5
InteractionMBD1 interactions

GRN MEGF6

1.43e-047752int:MBD1
InteractionATXN7 interactions

GRN MEGF6

2.87e-0410952int:ATXN7
InteractionCACNA1A interactions

GRN MEGF6

3.65e-0412352int:CACNA1A
InteractionGFI1B interactions

GRN MEGF6

4.46e-0413652int:GFI1B
InteractionDUT interactions

GRN MST1R

4.73e-0414052int:DUT
InteractionLRRFIP1 interactions

MST1R OLIG2

5.64e-0415352int:LRRFIP1
InteractionATN1 interactions

GRN MEGF6

8.41e-0418752int:ATN1
InteractionKRTAP6-2 interactions

GRN GALT

8.41e-0418752int:KRTAP6-2
ToppCellmild-Myeloid-CD14_Monocytes_2|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs

GRN MST1R

8.75e-05134528ba1f8d0af63bb7a802a002e72fe181b203cb451
ToppCellLPS-IL1RA-Endothelial-Mes-Like-Gen_Cap|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

MEGF6 MST1R

1.03e-041455290ca38c02325c5c637c32efdef634b54cc3cd105
ToppCelldroplet-Kidney-KIDNEY-30m-Epithelial-Epcam____podocyte-3|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MEGF6 MST1R

1.48e-041745276310c0af1d7df6a4de3816838b2ac2892f68746
ToppCellE18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-Mesothelial-Mesothelial_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

MEGF6 MST1R

1.54e-0417852c413861148129be1ee94f2ceb5999840217eebe5
ToppCellE18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-Mesothelial|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

MEGF6 MST1R

1.54e-0417852bcbdd45a2307f8aea14122fa0144b96b1f6eec48
ToppCellBALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Dendritic|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)

GRN MST1R

1.56e-04179528bd85ee92791996377bcafed198c1bb3c9af4c3c
ToppCellcellseq2-Immune-Immune_Myeloid-AM-AM|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

GRN OLIG2

1.60e-041815245fc9c27ea60312a118a2a6c1eb635d776fde295
ToppCellcellseq2-Immune-Immune_Myeloid-AM|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2

GRN OLIG2

1.60e-0418152d4ab8ab41bf3e6f1937e919662456d7c9551eeab
ToppCelldroplet-Kidney-nan-18m-Epithelial-Epcam____podocyte-3|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MEGF6 MST1R

1.69e-041865229c79b5a29907d4f3f87ad2ca04840c0f15b7d4e
ToppCellBAL-Mild-Myeloid-MoAM-MoAM3-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GRN OLIG2

1.82e-041935293ba635ed69fec9286fe7636b9d258f3d93a22c3
ToppCellBAL-Mild-Myeloid-MoAM-MoAM3|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

GRN OLIG2

1.82e-04193526dfdeb793cb5ad6412b6f808b5687a4e74b6ec65
ToppCellBAL-Mild-Myeloid-MoAM-MoAM3|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)

GRN OLIG2

1.83e-0419452e0cfd18a7ea2251163d61312b9397f8a518c8c51
ToppCellBAL-Mild-Myeloid-MoAM-MoAM3-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

GRN OLIG2

1.83e-0419452e455cb469157c044126f9b0b308957d4ee1e608b
ToppCell3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-elicited_macrophage|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

GRN OLIG2

1.85e-0419552ef2304acb01638df197f42dcc3db8c5867f4dc17
ToppCell3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-elicited_macrophage-Monocyte-derived_macrophage|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

GRN OLIG2

1.85e-04195525ed495941b80221206b8a9a86d92221ab8ba6682
ToppCellMild_COVID-19-Myeloid-MoAM3|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）

GRN OLIG2

1.87e-04196529faad17aa0b6af5a8ec2dadf7d70b9209d658072
ToppCellLPS_anti-TNF-Hematopoietic_Myeloid-Granulocytic_cells|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

GRN OLIG2

1.93e-04199527227e6be56e9f333ee143e1418d22de32a4ca66a
ToppCellParenchyma_Control_(B.)-Immune-TX-MoAM-3|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type

GRN OLIG2

1.93e-04199521ce46d9edabb3252f940a5143dd3f2404422d185
ToppCellLPS_anti-TNF-Hematopoietic_Myeloid-Granulocytic_cells-Neutrophils|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type

GRN OLIG2

1.93e-041995276aab03a51681f0ce3369887cf71a884b0998ec5
ToppCellLPS_only-Hematopoietic_Myeloid-Granulocytic_cells|LPS_only / Treatment groups by lineage, cell group, cell type

GRN OLIG2

1.95e-0420052c5afebbc16024c60e84a67be81c78b0bfb73ec68
ToppCellLPS_only-Hematopoietic_Myeloid-Granulocytic_cells-Neutrophils|LPS_only / Treatment groups by lineage, cell group, cell type

GRN OLIG2

1.95e-04200523504aeba7b30cac9c428ba3871c072e2202752b4
ComputationalGenes in the cancer module 121.

GRN MST1R

4.98e-049942MODULE_121
ComputationalImmune (defense) response.

GRN MST1R

1.02e-0314242MODULE_223
Drugisocitrate

GRN GALT

4.60e-0415652CID000001198
Drug15d-PGJ2; Up 200; 10uM; MCF7; HT_HG-U133A

MEGF6 MST1R

6.81e-04190525591_UP
DrugSimvastatin [79902-63-9]; Up 200; 9.6uM; MCF7; HT_HG-U133A

MEGF6 MST1R

7.10e-04194524828_UP
DrugAmprolium hydrochloride [137-88-2]; Up 200; 12.6uM; MCF7; HT_HG-U133A

MEGF6 MST1R

7.25e-04196524825_UP
DrugNaloxone hydrochloride [357-08-4]; Up 200; 11uM; MCF7; HT_HG-U133A

MEGF6 OLIG2

7.25e-04196525606_UP
DrugPempidine tartrate [546-48-5]; Up 200; 13uM; MCF7; HT_HG-U133A

MEGF6 MST1R

7.32e-04197523926_UP
DrugSulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; MCF7; HT_HG-U133A

MEGF6 OLIG2

7.32e-04197523940_UP
DrugOrlistat; Up 200; 10uM; MCF7; HT_HG-U133A

MEGF6 MST1R

7.32e-04197526383_UP
DrugVincamine [1617-90-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A

MST1R OLIG2

7.40e-04198523976_UP
Drugestradiol, USP; Up 200; 0.1uM; PC3; HT_HG-U133A

MEGF6 OLIG2

7.40e-04198524432_UP
DrugVincamine [1617-90-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A

MEGF6 MST1R

7.40e-04198523865_UP
DrugTerbutaline hemisulfate [23031-32-5]; Up 200; 7.2uM; MCF7; HT_HG-U133A

MEGF6 MST1R

7.47e-04199523202_UP
Drughaloperidol; Down 200; 10uM; MCF7; HG-U133A

MEGF6 MST1R

7.47e-0419952418_DN
Drugcelecoxib; Up 200; 10uM; MCF7; HG-U133A

MEGF6 OLIG2

7.55e-0420052377_UP
DrugAminopurine, 6-benzyl [1214-39-7]; Up 200; 17.8uM; MCF7; HT_HG-U133A

MST1R OLIG2

7.55e-04200523623_UP
DrugDimethyl Sulfoxide

GRN GALT

2.12e-0333752ctd:D004121
DrugMT19c compound

GRN OLIG2

4.57e-0349852ctd:C568376
Drugtamibarotene

GRN GALT

6.49e-0359652ctd:C061133
Diseasestatus epilepticus (biomarker_via_orthology)

GRN OLIG2

1.13e-0410052DOID:1824 (biomarker_via_orthology)
DiseaseSchizophrenia

GRN OLIG2

8.42e-0388352C0036341

Protein segments in the cluster

PeptideGeneStartEntry
VMVDGSWGCCPMPQA

GRN

141

P28799
AMMGCSNPHPHCQVW

GALT

176

P07902
CDPVHGQCHCAPGWM

MEGF6

1011

O75095
GQCHCAPGWMGPSCL

MEGF6

1016

O75095
QHWGGMPCPCSMCQV

OLIG2

286

Q13516
HFMGCGWCGNMCGQQ

MST1R

541

Q04912